OR WAIT null SECS
November 06, 2013
Merck Millipore has introduced a new solubility/bioavailability enhancement excipient, Parteck SLC, which has a unique pore structure that enables higher loading of amorphous APIs, thereby, improving dissolution rates and increasing drug solubility.
November 02, 2013
Fine-chemical companies, contract manufacturers, and researchers advance chemocatalysis and biocatalysis.
Data from BioPlan Associates’ 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.
Regulators hope new standards will stop illegal drug imports, but manufacturers fear they may stifle innovation.
October 24, 2013
Recent news and developments from CPhI of excipient producers, CDMOs, and CMOs are highlighted.
October 23, 2013
Excipients market will be shaped by greater supply-chain concerns, quality-by-design programs,and overall drug-safety issues.
October 10, 2013
With the enforcement of the European Directive 2011/62/EU relating to medicinal products for human use regarding falsified medicinal products, new requirements are introduced for active substances. The new regulation requires among other things, documentation of the supply chain traceability.
October 02, 2013
Fluorinated molecules play an important role as pharmaceutical compounds. Recent advances seek to overcome the challenges of selective and late-stage insertion of fluorine into small molecules.
September 27, 2013
Cedarburg Hauser Pharmaceuticals has upgraded its API plant in Wisconsin.
September 25, 2013
Pfizer advances its pipeline of antibody-based therapies using a host cell line that combines engineered glycosylation technology and enhanced gene-expression.
